Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Global cancer drug spending hits $100 billion in 2014: IMS Health

(Reuters) – Worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013 and up from $75 billion five years earlier, according to IMS Health’s Global Oncology Trend Report released on Tuesday. The $100 billion, which represents 10.8 percent of all drug spending globally and includes supportive care drugs […]

Read More »

China to stop setting most medicine prices from June 1

(Reuters) – China will remove price caps for most medicines from June 1 and give the market a larger role in setting prices in the world’s second largest pharmaceutical market, the country’s economic planning agency said on Tuesday. The change would encourage “reasonable” pricing of medicines and help control costs in the country’s state medical […]

Read More »

U.S. top court rejects hepatitis B drug patent case

(Reuters) – The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co’s attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers’ challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the patent. […]

Read More »

New Study Examines Success Lessons of Sovaldi’s and Harvoni’s Blockbuster Launches

CHAPEL HILL, N.C., May 1, 2015 /PRNewswire/ — The breakthrough hepatitis C treatment, Sovaldi faced backlash from payers for its high price but manufacturer Gilead Sciences overcame initial market resistance through its patient support programs, strategic worldwide pricing, and effective public relations campaigns. Sovaldi’s high cure rate, short dosing period, and promise of less severe […]

Read More »

Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra XR

MONMOUTH JUNCTION, N.J., May 1, 2015 /PRNewswire/ — Vernalis plc and Tris Pharma Inc. today announce that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III).  Tuzistra XR is an extended-release oral suspension combination of […]

Read More »

FDA Approves BREO ELLIPTA for the Treatment of Adults With Asthma in the US

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA–(Marketwired – Apr 30, 2015) – GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is […]

Read More »

FDA approves Glaxo, Theravance’s Breo Ellipta asthma drug

(Reuters) – The U.S. Food and Drug Administration on Thursday approved the sale of Breo Ellipta as a once-daily treatment for asthma in patients aged 18 and older, GlaxoSmithKline and Theravance Inc said.   The FDA declined to approve Breo for younger asthma sufferers. The agency, in a so-called complete response letter, told the companies […]

Read More »

FDA approves Medicines Co’s blood-clotting agent

(Reuters) – The U.S. Food and Drug Administration on Thursday approved The Medicines Co’s dry powder blood-clotting agent for use in hospital settings, a month after the treatment received approval in Europe. The treatment, Raplixa, is a combination of two human plasma-derived blood-clotting proteins – fibrinogen and thrombin. (1.usa.gov/1HVGQSd) Raplixa is used to control bleeding […]

Read More »

FDA approves BREO ELLIPTA for the treatment of adults with asthma in the US

LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ — GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the […]

Read More »

Eisai and Glenmark Reach Settlement over Generic Version of BANZEL (rufinamide)

WOODCLIFF LAKE, N.J., April 30, 2015 /PRNewswire/ — Eisai Inc. and Eisai Co., Ltd. have entered into a settlement agreement with Glenmark Pharmaceuticals, Ltd., Glenmark Generics Ltd., and Glenmark Generics, Inc., USA (“Glenmark”), to resolve their patent litigation relating to Eisai’s BANZEL® (rufinamide) in the United States. As a result of the settlement, Glenmark will be […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom